{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:37:08Z","timestamp":1790879828347,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ovarian carcinomas have the highest lethality amongst gynecological tumors. A problem after primary resection is the recurrence of epithelial ovarian carcinomas which is often associated with chemotherapy resistance. To improve the clinical outcome, it is of high interest to consider alternative therapy strategies. Due to their pronounced plasticity, \u03b3\u03b4 T cells are attractive for T-cell-based immunotherapy. However, tumors might escape by the release of lectin galectin-3, which impairs \u03b3\u03b4 T-cell function. Hence, we tested the effect of galectin-3 on the different \u03b3\u03b4 T-cell subsets. After coculture between ovarian tumor cells and V\u03b41 or V\u03b42 T cells enhanced levels of galectin-3 were released. This protein did not affect the cytotoxicity of both \u03b3\u03b4 T-cell subsets, but differentially influenced the proliferation of the two \u03b3\u03b4 T-cell subsets. While increased galectin-3 levels and recombinant galectin-3 inhibited the proliferation of V\u03b42 T cells, V\u03b41 T cells were unaffected. In contrast to V\u03b41 T cells, the V\u03b42 T cells strongly upregulated the galectin-3 binding partner \u03b13\u03b21-integrin after their activation correlating with the immunosuppressive properties of galectin-3. In addition, galectin-3 reduced the effector memory compartment of zoledronate-activated V\u03b42 T cells. Therefore, our data suggest that an activation of V\u03b41 T-cell proliferation as part of a T-cell-based immunotherapy can be of advantage.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1286097","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:11:50Z","timestamp":1704690710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3"],"prefix":"10.3389","volume":"14","author":[{"given":"Jan","family":"Schadeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Heinrich","family":"Oberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Hedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang W.","family":"Schamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Bauerschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Wesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040800","article-title":"Human gammadelta TCR repertoires in health and disease","volume":"9","author":"Fichtner","year":"2020","journal-title":"Cells"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.8.1067","article-title":"Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1-infected individuals","volume":"10","author":"Wesch","year":"1998","journal-title":"Int Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MA1119-265R","article-title":"Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors","volume":"107","author":"Oberg","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0503-y","article-title":"Ligand recognition by the gammadelta TCR and discrimination between homeostasis and stress conditions","volume":"17","author":"Deseke","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2713","article-title":"CD1d-lipid antigen recognition by the gammadelta TCR","volume":"14","author":"Uldrich","year":"2013","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300121","article-title":"Cutting edge: CD1d restriction and Th1\/Th2\/Th17 cytokine secretion by human V\u03b43 T cells","volume":"191","author":"Mangan","year":"2013","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100495200","article-title":"Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells","volume":"276","author":"Espinosa","year":"2001","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0817","article-title":"\u03b3\u03b4 T cells in merkel cell carcinomas have a proinflammatory profile prognostic of patient survival","volume":"9","author":"Gherardin","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"Vries","year":"2023","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284723","article-title":"Assessment of tumor-infiltrating TCRVgamma9Vdelta2 gammadelta lymphocyte abundance by deconvolution of human cancers microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705650","article-title":"Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation","volume":"39","author":"Godder","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0705-7","article-title":"How tumors might withstand gammadelta T-cell attack","volume":"68","author":"Capietto","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MR0717-275RR","article-title":"\u03b3\u03b4 cells and tumor microenvironment: A helpful or a dangerous liason","volume":"103","author":"Lo Presti","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/imr.12925","article-title":"Tumor resistance mechanisms and their consequences on gammadelta T cell activation","volume":"298","author":"Wesch","year":"2020","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01328","article-title":"Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses gammadelta T Cell Proliferation but Not Their Cytotoxicity","volume":"11","author":"Gonnermann","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0761","article-title":"A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice","volume":"70","author":"Demotte","year":"2010","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12242","article-title":"A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion","volume":"7","author":"Petit","year":"2016","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.215","article-title":"A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans","volume":"30","author":"Tsuboi","year":"2011","journal-title":"EMBO J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00109","article-title":"Turning-off signaling by siglecs, selectins, and galectins: chemical inhibition of glycan-dependent interactions in cancer","volume":"6","author":"Cagnoni","year":"2016","journal-title":"Front Oncol"},{"key":"B24","article-title":"Expression and clinical significance of Gal-3 and NF\u03baB pathway-related factors in epithelial ovarian carcinoma","volume":"13","author":"Luk","year":"2020","journal-title":"Int J Clin Exp Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1084\/jem.20090121","article-title":"Prognostic role of galectin-3 expression in patients with solid tumors: A meta-analysis of 36 eligible studies","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1159\/000050600","article-title":"Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16\/CA-125-expressing Malignancies","volume":"11","author":"Stasenko","year":"2021","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00305","article-title":"Antibodies against specific MUC16 glycosylation sites inhibit ovarian cancer growth","volume":"12","author":"Rao","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.6.3128","article-title":"New monoclonal antibody (23D12) recognizing three different V gamma elements of the human gamma delta T cell receptor. 23D12+ cells comprise a major subpopulation of gamma delta T cells in postnatal thymus","volume":"152","author":"Kabelitz","year":"1994","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.146.1.35","article-title":"T cell receptor\/CD3-signaling induces death by apoptosis in human T cell receptor gamma delta + T cells","volume":"146","author":"Janssen","year":"1991","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0675","article-title":"Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.8.5471","article-title":"In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model","volume":"175","author":"Sicard","year":"2005","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-417519","article-title":"Dysfunctional Vgamma9Vdelta2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells","volume":"120","author":"Coscia","year":"2012","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13505","article-title":"Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma","author":"Torres-Mart\u00ednez","year":"2023","journal-title":"Mol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.02894.x","article-title":"Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells","volume":"126","author":"Kunzmann","year":"2009","journal-title":"Immunology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1892265","DOI":"10.3390\/vaccines4040036","article-title":"Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity","volume":"10","author":"Sturgill","year":"2021","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1837","article-title":"Endothelial integrin \u03b13\u03b21 stabilizes carbohydrate-mediated tumor\/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane","volume":"5","author":"Glinskii","year":"2014","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature16064","article-title":"Oncogenic collagen I homotrimers from cancer cells bind to \u03b13\u03b21 integrin and impact tumor microbiome and immunity to promote pancreatic cancer","volume":"40","author":"Chen","year":"2022","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102182","article-title":"Redundant and antagonistic functions of galectin-1, -3, and -8 in the elicitation of T cell responses","volume":"188","author":"Tribulatti","year":"2012","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903497106","article-title":"Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2459","article-title":"A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes","volume":"20","author":"Demotte","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00521","article-title":"Integral roles for integrins in gammadelta T cell function","volume":"9","author":"Siegers","year":"2018","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1535730","article-title":"Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer","volume":"8","author":"Radestad","year":"2019","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12967-019-1897-0","article-title":"Distribution and functions of gammadelta T cells infiltrated in the ovarian cancer microenvironment","volume":"17","author":"Chen","year":"2019","journal-title":"J Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.03.003","article-title":"Tissue-specific expression of TIGIT, PD-1, TIM-3, and CD39 by \u03b3\u03b4 T cells in ovarian cancer","volume":"11","author":"Weimer","year":"2022","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites- and tumor-infiltrating \u03b3\u03b4 T cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci Transl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3MA0420-278RR","article-title":"Identification of a regulatory Vdelta1 gamma delta T cell subpopulation expressing CD73 in human breast cancer","volume":"107","author":"Chabab","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1111\/j.0006-341X.2001.00114.x","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3569","article-title":"CD73 is associated with poor prognosis in high-grade serous ovarian cancer","volume":"75","author":"Turcotte","year":"2015","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.973808","article-title":"Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy","volume":"4","author":"Fisher","year":"2015","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1286097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:11:53Z","timestamp":1704690713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1286097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2023.1286097"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1286097","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1286097"}}